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Objective: This study was carried out to determine the effects of vitamin D
supplementation on signaling pathway of inflammation and oxidative stress in diabetic
hemodialysis (HD) patients.
Methods: This randomized double-blind placebo-controlled clinical trial was conducted
among 60 diabetic HD patients. Subjects were randomly allocated into two groups to
intake either vitamin D supplements at a dosage of 50,000 IU (n= 30) or placebo (n= 30)
every 2 weeks for 12 weeks. Gene expression of inflammatory cytokines and biomarkers
of oxidative stress were assessed in peripheral blood mononuclear cells (PBMCs) of
diabetic HD patients with RT-PCR method.
Results: Results of RT-PCR indicated that after the 12-week intervention, compared to
the placebo, vitamin D supplementation downregulated gene expression of interleukin
(IL)-1β (P = 0.02), tumor necrosis factor alpha (TNF-α) (P = 0.02) and interferon
gamma (IFN-γ) (P = 0.03) in PBMCs of diabetic HD patients. Additionally, vitamin
D supplementation, compared to the placebo, downregulated gene expression of
transforming growth factor beta (TGF-β) (P = 0.04), protein kinase C (PKC) (P = 0.001),
and mitogen-activated protein kinases 1 (MAPK1) (P = 0.02) in PBMCs of diabetic
HD patients. Although not significant, vitamin D supplementation let to a reduction
of nuclear factor kappa B (NF-kB) (p = 0.75) expression in PBMCs isolated from
diabetic patients compared to the placebo group. There was no statistically significant
change following supplementation with vitamin D on gene expression of interleukin (IL)-4,
IL-6, and vascular endothelial growth factor (VEGF) in PBMCs of diabetic HD patients.
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Conclusions: Overall, we found that vitamin D supplementation for 12 weeks
among diabetic HD patients had beneficial effects on few gene expression related to
inflammation and oxidative stress.
Clinical trial registration: IRCT201701035623N101. Registered on January 8, 2017.
Keywords: vitamin D supplementation, hemodialysis, signaling pathway, inflammation, oxidative stress
INTRODUCTION
Increased inflammatory cytokines as a necessary part of chronic
kidney disease (CKD) has been identified and associated
with cardiovascular disease (CVD), protein-energy malnutrition,
all-cause mortality, and decreased glomerular filtration rate
(GFR) (Stenvinkel et al., 1999; Akchurin and Kaskel, 2015).
Increased biomarkers of inflammation, such as interleukin-
1beta (IL-1β) and tumor necrosis factor alpha (TNF-α) were
negatively linked to the measures of kidney action and directly
with albuminuria (Gupta et al., 2012). Furthermore, various
factors, including increased oxygen metabolism, uremic toxicity,
increased inflammatory factors, lack of antioxidant vitamins and
microelements, and dialysis procedure in patients with CKD
would result in oxidative stress (Stepniewska et al., 2015).
Prior studies have documented that hypovitaminosis D is
very prevalent in individuals with CKD (de Boer, 2008; Cupisti
et al., 2015). In a study by Bhan et al. (2010) hypovitaminosis
D was reported 50–90% in dialysis subjects. On the other hand,
beneficial effects of vitamin D on biochemical variables have
reported in hemodialysis (HD) patients (Ibrahim et al., 2015),
subjects with type 2 diabetes mellitus (T2DM) (Calvo-Romero
and Ramiro-Lozano, 2016) and polycystic ovary syndrome
(Maktabi et al., 2017). Few studies have evaluated the effects
of vitamin D on gene expression related to inflammation and
oxidative stress. Choi et al. (2013) shown significant reductions
in gene expression of interleukin 6 (IL-6) and tumor necrosis
factor alpha (TNF-α) in vitamin D-treated rats. In addition,
in vitro studies have shown that the release of TNF-α can be
inhibited by calcitriol in a dose-dependent fashion (Müller et al.,
1992). Another study indicated that vitaminD through vitaminD
receptor (VDR) suppressed TNF-α-induced nuclear factor kappa
B (NF-κB) activation and IL-6 up-regulation in epithelial cell
isolated from transgenic mice and colitis animal model (Liu
et al., 2013). However, another study supported no significant
changes in TNF-α and IL-6 levels in high-dose vitamin D
administration in healthy overweight individuals following a 12-
week progressive resistance exercise training program (Carrillo
et al., 2012).
The molecular mechanism of vitamin D in modulating
inflammatory cytokines and oxidative stress are still unclear.
Mitogen-activated protein kinases (MAPKs) participate in
signaling mechanisms in responses to pro-inflammatory factors
Abbreviations: HD, hemodialysis; PBMCs, peripheral blood mononuclear cells;
IL, interleukin; TNF-α, tumor necrosis factor alpha; IFN-γ, interferon gamma;
TGF-β, transforming growth factor beta; PKC, protein kinase C;MAPK1,mitogen-
activated protein kinases 1; VEGF, vascular endothelial growth factor; NF-κB,
nuclear factor kappa B; CVD, cardiovascular disease; CKD, chronic kidney disease;
GFR, glomerular filtration rate; VDR, vitamin D receptor; BMI, Body mass index.
as well as NF-κB are thought to play an important function
in the regulation of pro-inflammatory cytokines in cellular
responses (Baldassare et al., 1999). To our knowledge, data
on the effects of vitamin D supplementation on signaling
pathway of inflammation and oxidative stress in diabetic HD
patients are limited and controversial. The purpose of this study
was, therefore, conducted to evaluate the effects of vitamin
D supplementation on signaling pathway of inflammation and
oxidative stress in diabetic HD patients.
METHODS
Trial Design and Participants
This randomized double-blind placebo-controlled clinical trial,
registered in the Iranian website for registration of clinical trials
as http://www.irct.ir:IRCT201701035623N101, was carried out
among 60 diabetic HD subjects aged 18-80 years who were
referred to the Akhavan Clinic in Kashan, Iran, from January
2017 to April 2017. This research was carried out in accordance
with the Declaration of Helsinki and the Research Ethics
Committee of Kashan University of Medical Sciences (KAUMS)
approved the study protocol, and informed consent was taken
from all subjects. The main exclusion criteria from the study
were as follows: taking vitamin D, antioxidant and/or anti-
inflammatory supplements such as vitamins E and C, omega-3
fatty acids, and taking immunosuppressive medications within 3
months prior to the enrollment in the study.
Study Design
At first, all patients were randomized into two groups to receive
either 50,000 IU of vitamin D or placebo (n = 30 in each group)
every 2 weeks for 12 weeks. Vitamin D supplements and placebos
were produced by Zahravi Pharmaceutical Company, Tabriz,
Iran, and Barij Essence Pharmaceutical Company, Kashan, Iran,
respectively. In the current study, we used the above-mentioned
dose of vitamin D based on the tolerable upper intake level
(4,000 IU/day) of vitamin D (Ross et al., 2011), as well as dosage
recommended in previous studies among HD patients (Armas
et al., 2013; Mose et al., 2014). Compliance to the vitamin D
consumption was evaluated through determination of serum
25 (OH) vitamin D values and asking subjects to return the
medication containers. Both dietary 3-day food records [analyzed
by nutritionist IV software (First Databank, San Bruno, CA)] and
physical activity records were taken at baseline, weeks 3, 6, 9, and
12 of the intervention.
Assessment of Anthropometric Measures
Body weight and height were quantified in a fasting status using a
digital scale (Seca, Hamburg, Germany) at baseline and after the
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TABLE 1 | Specific primers used for real-time quantitative PCR.
Gene Primer Product Annealing
size (bp) temperature (C)
GAPDH F: GAGTCAACGGATTTGGTCGT 223 58
R: TTGATTTTGGAGGGATCTCG
IL1-β F: GATGGCTTATTACAGTGGCAATG 137 59
R: AGTGGTGGTCGGAGATTCG
IL-4 F: CTCACAGAGCAGAAGAACAC 221 60
R: TGGTTGGCTTCCTTCACAG
IL-6 F: GTAGTGAGGAACAAGCCAGAG 286 60
R: TGACCAGAAGAAGGAATGCC
TNF-α F: GAGCCAGCTCCCTCTATTTATG 187 60
R: CTACATGGGAACAGCCTATTGT
IFN-γ F: GGTTCTCTTGGCTGTTACTG 250 59.5
R: TGTCTTCCTTGATGGTCTCC
VEGF F: TGCAGATTATGCGGATCAAACC 150 58.5
R:TGCATTCACATTTGTTGTGCTGTAG
NFK-β F: GCTGAGTCCTGCTCCTTC 202 58
R: GTCTATTTGCTGCCTTGTGG
TGF-β F: ACTACTACGCCAAGGAGGTC 250 59
R: CGGTTGCTGAGGTATCGC
PKC F: CGTCCTCATTGTCCTCGTAAG 249 59
R: TCATTCCTGCTGGTCAAATCC
MAPK1 F: GGAACAGCACCTCCACTATTT 226 60
R: GCCACAATGTCTGCGTATCT
GAPDH, glyceraldehyde-3-Phosphate dehydrogenase; IL-1β, interleukin-1β; IFN-γ ,
interferon gamma; MAPK1, mitogen-activated protein kinases 1; NF-κB, nuclear factor
kappa B; PBMCs, peripheral blood mononuclear cells; PKC, protein kinase C; TNF-α,
tumor necrosis factor alpha; TGF-β, transforming growth factor beta; VEGF, vascular
endothelial growth factor.
12-week intervention. Body mass index (BMI) was calculated by
weight and height measurements [weight (kg)/height (m2)].
Assessment of Outcomes
Primary outcomes were inflammatory cytokines expression
and secondary outcomes were biomarkers of oxidative stress
expression. We selected the following inflammatory cytokines
and proteins [IL-1β, IL-4, IL-6,TNF-α, interferon gamma (IFN-
γ), transforming growth factor beta (TGF-β), protein kinase C
(PKC), MAPK1, vascular endothelial growth factor (VEGF) and
NF-κB] as they play a very important role in signaling pathways
of oxidative stress (Geraldes and King, 2010; Baker et al., 2011;
Tanti et al., 2012; Chen et al., 2015).
Isolation of Peripheral Blood Mononuclear
Cells (PBMCs)
At baseline and endpoint of the intervention, 15mL samples
of fasting blood were taken at reference laboratory of KAUMS,
Kashan, Iran. PBMCs were isolated from blood by centrifugation
through a Ficoll-Hypaque (Denholm andWolber, 1991) followed
by Percoll. In summary, 10mL of blood with an equal volume of
phosphate-buffered saline (PBS) was mixed (Dagur and McCoy,
2015). Layer diluted blood over Ficoll-Hypaque solution, using
3 parts diluted blood to 2 parts Ficoll-Hypaque and centrifuged
30min at 500 × g, 25◦C. Then, using a sterile Pasteur pipet,
carefully collected PBMCs, and located at the interface between
the plasma (upper layer) and Ficoll-Hypaque solution (Dagur
and McCoy, 2015). Cells to a 50mL centrifuge tube were
transferred, then after adding 10mL PBS, were centrifuged
10min at 400 × g, 4◦C. The supernatant was discarded and was
resuspended cells in 4mL PBS. Following previous step, 1.65mL
of 10× Hanks balanced salt solution with 10mL Percoll was
mixed. Eight mL Percoll solution with 4mL mononuclear cells
in a silanized 10 × 1.5 cm round-bottom polypropylene tube
was mixed (Dagur and McCoy, 2015). Mixing thoroughly by
inverting tube three or four times was done. Then, 25min at
370 × g, 25◦C was centrifuged. PBMCs were aspirated by gentle
pipetting into a clean test tube. After centrifugation, monocytes
appear as a cloudy layer in the top 5mm of the gradient (Dagur
and McCoy, 2015).
RNA Extraction and Real-Time PCR
To RNA extraction, we used the RNX-plus kit (Cinnacolon,
Tehran, Iran). RNA were extracted just after lymphocyte
extraction from fresh 5mL peripheral blood and less than
1 million cells was used for RNA extraction with the trizol
reagent (Invitrogen, USA). Following extraction of the total
RNAs from each sample, RNA quantification were performed
by UV spectrophotometer. Each samples OD 260/280 ratio
between 1.7 and 2.1 was intended showing no contamination
with both protein and DNA (Dunkley et al., 2008). The isolated
RNA was reverse transcribed to cDNA library using moloney
murine leukemia virus reverse transcriptase. Gene expression
of IL-1β, IL-4, IL-6,TNF-α, IFN-γ, TGF-β, PKC, MAPK1,
VEGF, and NF-κB were evaluated by quantitative RT-PCR,
using the LightCycler technology (Roche Diagnostics, Rotkreuz,
Switzerland) with SYBR green detection and Amplicon Kit
(Table 1). Glyceraldehyde-3-phosphate dehydrogenase primers
were used as housekeeping gene. To design primers, Primer
Express Software (Applied Biosystems, Foster City) and Beacon
designer software (Takaposizt, Tehran, Iran) were used. Relative
transcription levels were calculated by the method of Pffafi or
2−11CT. In the current study, we quantified gene expression
levels related to inflammation and oxidative stress in PBMCs
from diabetic HD patients. PBMCs from venous blood samples
are the most available tissue for analysis of gene expression
(Mizuarai et al., 2010). In addition, gene expression levels
related to inflammation and oxidative stress in PBMCs are
more accurate and may provide more valuable information than
plasma concentrations (Mizuarai et al., 2010). Few studies have
previously assessed gene expression levels of inflammation and
oxidative stress in PBMCs from diabetic patients (Xavier et al.,
2015; Mazloom et al., 2016).
Randomization
Randomization assignment was carried out using
computer-generated random numbers. Randomization and
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FIGURE 1 | Summary of patient flow diagram.
allocation concealment were conducted by the researchers and
participants and were carried out by a trained staff at the clinic.
Statistical Methods
The Kolmogorov-Smirnov test was applied to control the normal
distribution of variables. Independent sample t-test was used
to establish changes in anthropometric measures and dietary
intakes between the two groups. To determine the effects
of vitamin D administration on inflammation and oxidative
stress expression, we used independent sample t-test. P < 0.05
were considered statistically significant. All statistical analyses
conducted using the Statistical Package for Social Science version
18 (SPSS Inc., Chicago, Illinois, USA).
RESULTS
Sixty diabetic HD patients [vitamin D and placebo (n = 30
each group)] completed the trial (Figure 1). On average, the
rate of compliance in our study was high, such that more than
100% of capsules were taken throughout the study in both
groups. No side effects were reported following supplementation
of vitamin D in diabetic HD patients throughout the study.
Potential side effects of vitamin D supplementation monitored
by evaluating the serum levels of calcium every month, as well
as, monitoring clinical symptoms among participants including,
anorexia, nausea, and vomiting.
Distribution of gender, participants’ mean age, height, baseline
weight and BMI as well as their change, and years of dialysis of
study participants were not statistically different between the two
groups (Table 2).
Considering the 3-day dietary records obtained during the
intervention, there was no significant difference in terms of
dietary macro- and micro-nutrient intakes between vitamin D
and placebo groups (Data not shown).
After 12 weeks of intervention, compared to the placebo,
vitamin D supplementation significantly increased serum 25-
OH-vitamin D (+11.1 ± 4.2 vs. +0.5 ± 3.9 ng/mL, P < 0.001).
Results of RT-PCR indicated that compared to the placebo,
vitamin D supplementation downregulated gene expression of
IL-1β (P = 0.02), TNF-α (P = 0.02), and IFN-γ (P = 0.03)
in PBMCs of diabetic HD patients (Figure 2). There was no
statistically significant change following supplementation with
vitamin D on gene expression of IL-4 and IL-6 in PBMCs of
diabetic HD patients.
Additionally, vitamin D supplementation, compared to the
placebo, downregulated gene expression of TGF-β (P = 0.04),
PKC (P = 0.001), and MAPK1 (P = 0.02) in PBMCs of diabetic
HD patients (Figure 3). Although not significant, vitamin D
supplementation let to a reduction of NF-kB (p = 0.75)
expression in PBMCs isolated from diabetic patients compared
to the placebo group. We did not observe any significant change
following supplementation with vitamin D on gene expression of
VEGF in PBMCs of diabetic HD patients.
DISCUSSION
We found that vitamin D supplementation for 12 weeks among
diabetic HD patients had beneficial effects on few gene expression
related to inflammation and oxidative stress. To our knowledge,
this is the first report of the effects of vitamin D supplementation
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TABLE 2 | General characteristics of study participants.
Placebo group Vitamin D group Pa
(n = 30) (n = 30)
GENDER (%)
Male 20 (66.7) 19 (63.4) 0.78†
Female 10 (33.3) 11 (36.6)
TYPE OF DIABETES (%)
Type 1 2 (6.7) 2 (6.7) 1.00†
Type 2 28 (93.3) 28 (93.3)
Smoking (%) 3 (10.0) 3 (10.0) 1.00†
Duration of DM (year) 18.9 ± 6.0 19.1 ± 5.4 0.87
Insulin therapy (%) 30 (100.0) 30 (100.0) 1.00†
Age (y) 60.7 ± 14.3 57.1 ± 13.4 0.31
Height (cm) 162.5 ± 8.0 163.5 ± 8.1 0.65
Weight at study baseline (kg) 71.2 ± 15.7 69.5 ± 11.8 0.65
Weight at end-of-trial (kg) 71.2 ± 15.7 70.1 ± 11.9 0.75
Weight change (kg) 0.008 ± 1.3 0.5 ± 1.3 0.12
BMI at study baseline (kg/m2) 27.0 ± 6.0 26.1 ± 4.5 0.51
BMI at end-of-trial (kg/m2) 27.0 ± 5.9 26.3 ± 4.5 0.61
BMI change (kg/m2) 0.002 ± 0.5 0.2 ± 0.5 0.11
Years on dialysis 3.7 ± 1.0 3.9 ± 1.2 0.56
Cancer (%) 2 (6.7) 2 (6.7) 1.00†
CAD (%) 22 (73.3) 21 (70.0) 0.77†
CVD (%) 5 (16.7) 6 (20.0) 0.73†
Hypertension (%) 28 (93.3) 29 (96.7) 0.55†
Data are means ± SDs.
aObtained from independent t-test.
†
Obtained from Pearson Chi-square test.
CAD, coronary artery disease; CVD, cerebrovascular disease; DM, diabetes mellitus.
on gene expression related to inflammation and oxidative stress
in diabetic HD patients.
HD subjects are susceptible to several metabolic
complications, including increased inflammation and oxidative
stress (Kotur-Stevuljevic et al., 2012). Our data demonstrated that
vitamin D supplementation for 12 weeks to diabetic HD subjects
downregulated gene expression of IL-1β, TNF-α, and IFN-γ
compared to the placebo, but did not affect gene expression of
IL-4 and IL-6. A study in healthy endurance-trained runners
has demonstrated the inverse relationship between vitamin
D and TNF-α levels (Willis et al., 2012). Furthermore, in line
with our findings, 50 mug/day of vitamin D supplementation
for 9 months was able to suppress the production of TNF-α
in subjects with congestive heart failure (Schleithoff et al.,
2006). 1,25-(OH)2D3 dose-dependently also suppressed the
production of IL-α, IL-6, and TNF-α by Escherichia coli
lipopolysaccharide-stimulated monocytes (Müller et al., 1992).
However, one study has documented no significant changes
in TNF-α and IL-6 concentrations in high-dose vitamin D
supplementation-healthy overweight populations after 12
weeks (Carrillo et al., 2012). Chronic inflammation in CKD
is not only associated with macro- and micro-cardiovascular
outcomes, such as atherosclerosis, but is also one of the
main players in the progress of malnutrition/protein-energy
wasting, which in turn resulted in the description of the
malnutrition-inflammation-cachexia syndrome in CKD/ESRD
patients (Kalantar-Zadeh, 2005). Hypoalbuminemia result from
chronic inflammation and malnutrition is strongly related to
mortality in dialysis populations (Kalantar-Zadeh et al., 2005;
FIGURE 2 | Effect of 12-week supplementation with vitamin D or placebo on expression ratio of TNF-α, IFN-γ, IL-1β, IL-4, and IL-6 genes in PBMCs of diabetic HD
subjects. P-value was obtained from independent sample t-test. Data are means ± standard deviation.
FIGURE 3 | Effect of 12-week supplementation with vitamin D or placebo on expression ratio of PKC, MAPK1, TGF-β, NF-κB, and VEGF genes in PBMCs of diabetic
HD subjects. P-value was obtained from independent sample t-test. Data are means ± standard deviation.
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de Mutsert et al., 2009). Pro-inflammatory factors may directly
lead to anorexia via the effect on the brain. Furthermore,
inflammatory cytokines, particularly IL-6, may be related to
depression in CKD/ESRD patients, which by itself is a predictor
of morbidity and mortality (Taraz et al., 2015) and may result
in decreasing nutrient intake. Therefore, vitamin D due to
its useful effects on inflammatory cytokines may be benefit
to decrease clinical and metabolic symptoms in diabetic HD
patients.
This study demonstrated that vitamin D supplementation
for 12 weeks downregulated gene expression of TGF-β, PKC,
and MAPK1 in PBMCs of diabetic HD patients, but did not
influence gene expression of VEGF and NF-Kβ. Supporting
our study, vitamin D administration at a dosage of 50,000
IU/week for 8 weeks in VD-deficient subjects with PCOS
significantly decreased the bioavailability of TGF-β1 (Irani et al.,
2015). In addition, 1,25-(OH)2D3 decreased gene expression
of MAPK phosphorylation in macrophages (Xu et al., 2016).
In another study, vitamin D protected human endothelial cells
from ionizing radiation induced/oxidative stress by modulating
the MAPKs/SirT1 axis (Marampon et al., 2016). Doxercalciferol
also significantly decreased PKCα levels suggesting that PKC-
mediated cardiac hypertrophy may be related to vitamin
D deficiency (Choi et al., 2011). Excessive evidence exists
suggesting that MAPK signaling pathways are critical for the
synthesis and amplification of inflammatory factors (Carter
et al., 1999). Especially, MAPK activation was closely associated
with cytokine transcription and translation, which in turn
make the target of anti-inflammatory treatment (Kaminska,
2005). However, calcitriol treatment had no significant effect on
gene expression of TGF-β in microcardiovascular endothelial
cells (Gonzalez-Curiel et al., 2016). In addition, both the low
(1 nM) and the high (100 nM) doses of vitamin D3 used in
vitro for 48 h did not able to restore the decreased gene
expression of PKC isoenzymes in the T cells of systemic lupus
erythematosus subjects (Czifra et al., 2014). Oxidative stress in
patients with CKD may generate by uremic toxicity, persistent
inflammatory state, deficiency of vitamins and microelements,
and dialysis procedure itself (Stepniewska et al., 2015). Increased
biomarkers of oxidative stress and free radicals in HD
subjects are correlated with increased CVD risk and a large
number of diseases related to uremia (Taccone-Gallucci et al.,
2010).
CONCLUSIONS
Overall, we found that vitamin D supplementation for 12
weeks among diabetic HD patients had beneficial effects on
some gene expression related to inflammation and oxidative
stress. This suggests that vitamin D supplementation may confer
advantageous therapeutic potential for HD patients. Further
research is needed in other participants and for longer periods
to determine the efficacy of vitamin D supplementation.
LIMITATIONS
The limitations of our findings include short duration.
Long-term interventions might result in better effects in
other gene expression related to inflammation and oxidative
stress. In addition, due to funding limitations in developing
countries, we did not evaluate some gene expression related
to insulin and lipid, and reactive oxygen species levels.
Further investigations are required to evaluate this outcome.
We did not know baseline levels of vitamin D among our
participants, therefore, we were not able to comment on
their commended dosage of vitamin D by the Kidney Disease
Outcomes Quality Initiative (K/DOQI) guidelines. This
limitation should be considered in the interpretation of our
findings.
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